about
Aptamers: A Feasible Technology in Cancer ImmunotherapyAptamers: A New Technological Platform in Cancer ImmunotherapyIdiotype vaccines for human B-cell malignanciesA phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma.Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.Dendritic cell vaccination in glioblastoma after fluorescence-guided resectionIdentification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy.MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cellsStem cell transplant and idiotypic vaccination for B-cell malignancies.Idiotype vaccines for lymphoma therapy.Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers.Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia.Idiotype vaccine production using hybridoma technology.Prolonged idiotypic vaccination against follicular lymphoma.Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decayTumor-targeted costimulation by using bi-specific aptamers.Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA).BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.SC-01HnRNPA1 PROTEIN DEREGULATES Baf45d mRNA SPLICING IN GLIOMA: FUNCTION AND MECHANISM.Anti-inflammatory cytokines induce lipopolysaccharide tolerance in human monocytes without modifying toll-like receptor 4 membrane expression.The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma.In Silico Aptamer Docking Studies: From a Retrospective Validation to a Prospective Case Study-TIM3 Aptamers Binding.Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy.Targeting inhibition of Foxp3 by a CD28 2'-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy.Aptamer-iRNAs as Therapeutics for Cancer TreatmentClinical benefit associated with idiotypic vaccination in patients with follicular lymphomaLipopolysaccharide needs soluble CD14 to interact with TLR4 in human monocytes depleted of membrane CD14Successful idiotypic vaccination following stem cell allotransplant in lymphomaAn RNA toolbox for cancer immunotherapyIntratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors
P50
Q26740303-A8454F9C-0170-4A50-9E11-90815A6E7220Q28068981-B9D00B0F-6571-4D62-B3B3-4278B426C19FQ28271598-F6D436A8-168C-4D80-A40B-9DDB29626485Q33668084-90D97983-F0AA-4A8B-98A8-38DC590371F8Q36074726-DD1E1043-DD78-4657-8794-ECE5451C848EQ36183600-6D1A01C5-5D60-4C89-9FC1-4A84895F7585Q36507978-420ACC1C-C044-45B5-8187-7993425C5DB7Q36782499-F58DD3C6-D34A-4ADF-AE86-58CC00E40FF3Q37268962-71CA31D7-0E65-452D-9357-6A8C0A2E1FDCQ37859048-9B902EB0-880C-48F8-AAFC-02622A581652Q37892587-B316BDA9-9324-44CC-99B4-C6A2AFC812AAQ38332777-3199C822-69B9-41F3-8338-B5DFF57F84E7Q38576510-035CEE1F-A00A-4E8D-845E-AAEE4B345F1BQ38847477-26942F6D-A03F-40AE-8C7C-F4F4FD384745Q39016363-89C5CD81-8818-492F-8441-EAFF5565020CQ39209899-BFF78938-3696-4D98-BF19-381FDFD09A4CQ39704510-79C2E2C0-5946-4DAA-B53C-D64573AAA954Q42114652-76AC064B-9DDA-414C-96DB-9BAC09CBA876Q42362135-32290946-7825-42A9-8E49-32D16E5E39F4Q43905270-B9AC0A43-5DF9-4026-BCA2-E614312CB18FQ46952124-C10F85FA-ED3A-4747-8F27-E2768C52DE47Q47384039-D9B09A9C-72B5-439E-BE11-2701A5488968Q47837824-72CAE4D7-3538-4AF3-B481-D406C4892E71Q51380809-9E46BB2D-2D23-46EA-83DC-D76CC6763534Q52687811-C0B374E3-D147-4434-9332-4F9338B58DA4Q53141619-C5E67FC0-B732-4DD2-A578-266384479900Q57812842-D41F43AF-F16A-4C72-B677-5E88EA702028Q80294344-2210AC80-E529-45D7-A92E-4B6BA80B5354Q80521520-0D16F533-CA24-42F1-B508-FD0150E49AC2Q84810383-0DEA34F4-F003-4E6F-8FC4-10B31D0BFD8FQ91322503-B3D9270C-9365-42AB-8756-670ABA652F6AQ91473720-76FCC346-E273-4F6A-A24E-2AE44C8467FB
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Fernando Pastor
@ast
Fernando Pastor
@en
Fernando Pastor
@es
Fernando Pastor
@nl
Fernando Pastor
@sl
type
label
Fernando Pastor
@ast
Fernando Pastor
@en
Fernando Pastor
@es
Fernando Pastor
@nl
Fernando Pastor
@sl
prefLabel
Fernando Pastor
@ast
Fernando Pastor
@en
Fernando Pastor
@es
Fernando Pastor
@nl
Fernando Pastor
@sl
P106
P21
P31
P496
0000-0003-0432-3133